Stocks · News reference
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over losses of $(0.86) per
8-K filing — PALVELLA THERAPEUTICS, INC. (PVLA)
Filed: 2026-08-04 AccNo: 0001193125-26-331556 Size: 12 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits